GET THE APP

..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Articles in press and Articles in process

    Case Report Pages: 1 - 3

    'Cholestatic Jaundice as a Revealing Manifestation of a Metastatic Prostate Cancer: A Case Report

    Ilham Khalfaoui

    DOI: 10.37421/2376-1318.2024.13.345

    Cholestatic jaundice as the initial symptom in patients with metastatic prostate cancer is extremely rare. Few cases only of paraneoplasic cholestatic jaundice associated with prostate cancer have been reported in the literature. We present a case of 57 years old patient who presented cholestatic jaundice revealing an underlying metastatic prostate cancer after detailed examinations including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positon Emission Tomography (PET), and Endoscopic Retrograde Cholangiopancreatography (ERCP). Cholestatic jaundice may be brought on by malignancies via identified pathways (e.g., bile duct obstruction or widespread hepatic infiltration). Through an unknown pathogenetic mechanism, paraneoplastic syndromes connected to malignancy, particularly renal cell carcinoma (Stauffer's syndrome) and malignant lymphoproliferative disorders, can cause a reversible form of cholestasis. There have been two cases documented in the medical literature of prostate cancer that originally manifested as cholestatic jaundice without any clear reason (i.e., blockage or invasion). We describe a patient who had pruritus and cholestatic jaundice when they first arrived. The diagnosis of prostate cancer was made throughout the diagnostic process. Conjugated bilirubin and alkaline phosphatase levels significantly rose, but transaminase and glutamyltranspeptidase levels only slightly increased. No signs of extrahepatic biliary blockage or hepatic metastases were found, according to the findings of the necessary studies carried out while the patient was hospitalised.

    Research Article Pages: 1 - 13

    Cancer and its Associated Factors in India: A Study Based on the National Family Health Survey (NFHS) 2015-16

    Cheryl Anandas1

    DOI: 10.37421/2167-1168.2024.13.682

    According to the NICPR in the year 2010, the average estimated prevalence of cancer was 25 lakhs and incidence was about 07 lakhs in India, there were 5.56 lakh deaths due to cancer. The study is based on data from NFHS (2015-16). Univariate and Bivariate analysis and Poisson regression models were used to establish an association between all independent predictors and outcome variable. Among both women and men, asthma and diabetes emerged as the main determinants for cancer prevalence. Women who smoke tobacco are 1.76 times significantly more likely to get cancer whereas in case of men who smoke are 2.65 times significantly more likely to get cancer. Among both women and men, non-vegetarian diet emerged to be important determinants for cancer prevalence i.e. (IRR=1.58, P<0.05) for women and (IRR=3.17, P<0.05) for men. Among women who are exposed to arsenic through groundwater are 1.81 times significantly more likely to get cancer. From the study, it has been found that asthma and diabetes among biological factors; tobacco and alcohol consumption, consumption of non-vegetarian food and arsenic exposure (only among women) among behavioral factors are the main determinants of cancer prevalence among both men and women in India.

    Research Article Pages: 1 - 5

    Liver Inflammation Parameters in Relation to Survival in Patients with Hepatocellular Carcinoma Tumor of differing Sizes

    Brian Carr*, Vito Guerra, Ümit Karaoğullarından, Hikmet Akkiz, Volkan Ince, Burak Isik and Sezai Yilmaz

    DOI: 10.37421/2167-1168.2024.13.682

    Introduction: Survival in patients with Hepatocellular Carcinoma (HCC) has been previously found to be worse with increase in tumor size, but also with increase in inflammation. To examine these issues separately, we aimed to study the influences on survival of various liver inflammation parameters in the whole cohort, and separately in patients with HCCs of defined Maximum Tumor Diameter (MTD).

    Methods: A prospectively collected large database of Turkish HCC patients with documented survival was interrogated. Patients had baseline liver function tests and CT scans for tumor characteristics. Liver function and inflammation parameters included blood tests for levels of albumin, AST, GGT, ALKP, CRP, ESR and WBC.

    Results: Survival was worse for patients with larger HCCs, including those with low or high serum AFP levels. Highest hazard ratios were found for patients with abnormal blood albumin (low) or AST (high) levels, regardless of AFP status. When patients were separately examined according to tumor size, only albumin and AST were significant for survival in patients with small <3cm tumors; whereas albumin, AST and ALKP were significant in patients with >3cm HCCs. Abnormal albumin or AST levels in different HCC size cohorts significantly related to percent patients with PVT, higher AFP or increased tumor focality, regardless of tumor size.

    Results: Survival was worse for patients with larger HCCs, including those with low or high serum AFP levels. Highest hazard ratios were found for patients with abnormal blood albumin (low) or AST (high) levels, regardless of AFP status. When patients were separately examined according to tumor size, only albumin and AST were significant for survival in patients with small <3cm tumors; whereas albumin, AST and ALKP were significant in patients with >3cm HCCs. Abnormal albumin or AST levels in different HCC size cohorts significantly related to percent patients with PVT, higher AFP or increased tumor focality, regardless of tumor size.

Google Scholar citation report
Citations: 5332

Cancer Science & Therapy received 5332 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward